How Indian women’s go-to drug, Meftal Spas, became a victim of its own popularity

It wont be a stretch to say that the Meftal Spas is life-changing for those who suffer from dysmenorrhea. The medicine which is a combination mefenamic acid and dicyclomine was launched more than 40 years ago by Blue Cross Labs, an Indian pharma company. Meftal Spas enjoys the lion’s share of the market at nearly 90%.

But at the end of November last year, the Indian Pharmacopoeia Commission (IPC), an autonomous body under the Ministry of Health and Family Welfare, issued a  drug safety alert  on mefenamic acid—one of the two main components of Meftal Spas.

Soon after, many regular users started avoiding the medicine and some hospitals even stopped prescribing it. In fact, pharmacies saw a marked drop in Meftal Spas sales .

But media reports were misleading. While the advisory was about mefenamic acid, many media houses reported that the advisory was about Meftal Spas. And that is not all, many health professionals are questioning the govt advisory itself.

Tune in.

Daybreak is produced from the newsroom of The Ken, India's first subscriber-only business news platform. Subscribe for more exclusive, deeply-reported, and analytical business stories